Navigation Links
Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial

ing its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; the ability of the company to attract and retain qualified personnel; competition in general; the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries and the Company's ability to accurately assess the market. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2006 and filed with the Securities and Exchange Commission, the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 and other filings that the company makes with the Securities and Exchange Commission.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

(1) Center For Disease Control National Prevention Strategy.

(2) Center for Disease Control. Hepatitis C Fact Sheet accessed online at http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm.

(3) Davis, G. et al., Projecting Future Complications of Chronic Hepatitis C in the United States. Liver Transplantation, April 2003.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 99
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver
2. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
3. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
4. Low-Dose Steroid Combined With Lenalidomide Prolongs Survival Compared With High-Dose Steroid for Multiple Myeloma Treatment
5. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
8. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
9. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
10. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
11. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Post Your Comments:
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Inc. (Nasdaq: MYL ) and Pfizer Inc. (NYSE: ... a Pfizer subsidiary, has entered into a settlement agreement with ... abbreviated new drug application (ANDA) for a generic epinephrine auto-injector. ... Teva may launch a generic epinephrine auto-injector covered by its ...
... 2012 Shire plc (LSE: SHP, NASDAQ: ... for the three months to March 31, 2012. ... $1,172 Total revenues million +21% Non GAAP operating income $362 ... GAAP diluted earnings per ADS $1.48 +20% US GAAP diluted ...
Cached Medicine Technology:Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva 2Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 2Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 3Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 4Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 5Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 6Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 7Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 8Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 9Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 10Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 11Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 12Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 13Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 14Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 15Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 16Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 17Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 18Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 19Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 20Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 21Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 22Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 23Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 24Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth 25
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/8/2014)... similar longevity and cardiovascular health as other healthy mature ... American Journal of Transplantation . The findings may ... the transplant professionals caring for them. , Over the ... 55 years and older has become more common. Given ... disease, the removal of a kidney could make older ...
(Date:7/8/2014)... from Plymouth, UK, and Sydney, Australia, have today (Wednesday ... ACEmobile - a free-to-use app to support the assessment ... first of its kind; an iPad-based tool that supports ... the whole process, meaning more members of the clinical ... assessment. Designed by clinicians for clinicians, ACEmobile also collects ...
(Date:7/8/2014)... a biomarker that could give expecting mothers and their ... that a pregnant woman may develop preeclampsia, at least ... Preeclampsia is a cardiovascular disorder generally occurring late in ... immediate and potentially lifelong risks to both mother and ... the urine, and is typically diagnosed in the late ...
Breaking Medicine News(10 mins):Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... series feature eight model methods for effective prospect ... has released its first in a series of ... are using prospect research efficiently and with success ... fundraising, includes survey responses from 60 hospitals and ...
... 1 on annual listOAKLAND, Calif., March 5 ... has been recognized by DiversityMBA ... organization was ranked No. 1 in the publication,s fourth ... for Diverse Managers to Work," which will hit newsstands ...
... To Beaver, Star Jerry MathersJACKSON, Miss., March 5 ... will be stopping in Mississippi the week of March ... to help uninsured and financially-struggling Mississippians access information on ... free. With the unemployment rate in Mississippi (7.8 percent) ...
... for low intake of Omega-3 EPA/DHA amongst , childrenHALIFAX, ... the Journal of Nutrition found that most Canadian children ... 78% of the children trialed were not receiving adequate ... , Researchers from the University of Guelph ...
... ANGELES, March 5 With the nation focused on ... recently announced Assembly Bill 562 ( AB ... businesses and consumers that have fallen victim to price ... health care premium costs. It requires insurance companies to ...
... 5 Ascension Insurance, Inc. has announced ... Lauderdale, effective January 16th 2009. The agency specializes in ... (EMI), a member of the Ascension group of companies ... the Ascension group is managed by Ascension Insurance, Inc. ...
Cached Medicine News:Health News:WealthEngine Releases Best Practices Report for Healthcare Fundraising 2Health News:Kaiser Permanente Recognized as Best Place for Diverse Managers 2Health News:Kaiser Permanente Recognized as Best Place for Diverse Managers 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 2Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 3Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 4Health News:New Health Care Legislation Stops 'Opportunistic' Insurance Pricing 2Health News:Ascension Insurance, Inc. Acquires Fort Lauderdale-based Dennis Bartlett Agency 2
Our 2.5v Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
... are standard in all Welch Allyn ... students, the 18335-SDS combines the superior ... the superior illumination of the Halogen ... of the Finnoff Transilluminator, and the ...
Our 2.5v Streak Retinoscope Sets feature instruments with bright light, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products: